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INTRODUCTION
INTRODUCTION 
Hirsutism is a disorder which affects about 10 to 15 percent of women. 
Hirsutism is the most frequent androgen excess disorder in women1. Hirsutism is 
defined as the excessive growth of terminal hair in androgen dependent areas of a 
woman’s body. The sites affected include  
• The upper lip 
• Chin  
• Chest 
• Upper abdomen 
•  Lower abdomen 
• Upper  back  
• Lower back 
• Upper Arm 
• Thighs 
Each of the nine areas is given a score of 0 to 4 depending upon the grade 1 –
mild, 2-moderate, 3-complete light coverage and 4 for complete heavy coverage.  
A score of more than 15 is considered as severe hirsutism2. Occasionally, 
hirsutism may signal more serious pathology. Therefore, clinical evaluation 
should differentiate benign causes from tumours and other conditions that require 
specific treatment. 
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PICTURE NO.1 
PICTURE OF A SUBJECT WITH EXCESSIVE HAIR IN THE ABDOMEN 
 
 
 
 
 
 
 
 
 
Hirsutism should be differentiated from hypertrichosis. Hypertrichosis is 
defined as a diffuse increase in vellus hair growth and is not androgen dependent. 
The congenital causes of hypertrichosis include Hurlers syndrome, trisomy 18, 
fetal alcohol syndrome etc. The other causes include hypothyroidism, porphyrias, 
epidermolysis bullosa, anorexia nervosa, malnutrition, dermatomyositis, severe 
head injury and trauma.3. 
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Drugs causing hypertrichosis4 
• Cyclosporin (Sandimmune) 
• Diazoxide (Hyperstat) 
• Hydrocortisone 
• Minoxidil (Rogaine) 
• Pencillamine (Cuprimine) 
• Phenytoin (Dilantin) 
• Psoralens (Oxsoralen) 
• Streptomycin 
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PICTURE NO.2 
SOURCES OF ANDROGENS IN ADULT WOMEN 
                Approximately one-half of a woman’s serum testosterone is derived 
from peripheral conversion of secreted androstenedione, and the other-half is 
derived from direct glandular secretion. The ovaries and adrenal glands 
contribute almost equally to the direct glandular testosterone production in 
women1.  
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PATHOGENESIS OF HIRSUTISM 
Hirsutism can result from an increase in androgen level or due to the 
oversensitivity of the hair follicles to androgen. Large quantities of circulating 
androgens are bound to sex hormone binding globulin (SHBG), cortisol- binding 
globulin and albumin. The free testosterone is the main bioactive component of 
plasma testosterone. The SHBG can decrease in the body in many conditions such 
as obesity, hyperinsulinemia or after administration of androgens, synthetic 
progestins, glucocorticoids and growth hormones. With the reduction in the 
SHBG levels in the body, the free testosterone level increases which can result in 
hirsutism. However the severity of hirsutism does not correlate well with the level 
of the androgen. This is because the sensitivity of hair follicles to androgen varies 
among individuals.  The enzyme 5 alpha-reductase type 1 converts testosterone to 
the highly active dihydrotestosterone .5 
In an update on hirsutism, it was stated that familial clustering of PCOS, 
hyperandrogenism and hirsutism suggest a genetic etiology. Environmental 
factors might also be the triggering agents in some families. Recent experimental 
evidence supports the hypothesis of intrauterine environment influencing 
hyperandrogenic phenotype in adult life.5 
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                                        PICTURE NO.3 
PICTURE OF A SUBJECT WITH EXCESSIVE FACIAL HAIR 
 
 
Both insulin and LH stimulate ovarian theca cell androgen production. As a 
result, affected ovaries secrete elevated levels of testosterone and 
androstenedione6. 
  Insulin resistance independent of obesity has also been described as 
pathognomonic of PCOS7. Clinically, PCOS is characterized by menstrual 
irregularities, hyperandrogenism, hyperinsulinemia and long term metabolic 
disturbances such as diabetes mellitus, cardiovascular disease and dyslipidemias8. 
Insulin  and body fat play an important role in regulating lipid levels9. 
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PICTURE NO.4 
PICTURE OF A SUBJECT WITH EXCESSIVE CHEST HAIR 
 
 
 
 
 
 
 
 
 
 
 
       Although both testosterone and DHT convert short, soft vellus hair to 
coarse terminal hair, DHT is markedly more effective than testosterone. 
Conversion is irreversible and hence only hairs in androgen sensitive areas are 
changed in this manner to terminal hairs6. 
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CAUSES OF HIRSUTISM 
Hirsutism is one sign of hyperandrogenism. Hirsutism can be familial, 
idiopathic, due to excess androgen secretion by the ovary and adrenal glands or 
from exogenous sources of androgens such as medications. 
¾ Idiopathic hirsutism is often familial. The onset occurs shortly after 
puberty with slow progression. They have normal menses and normal 
androgen levels.3 
¾ Ovarian causes-PCOS, androgen secreting ovarian tumors, menopause.  
The cardinal features of PCOS are hyperandrogenism and polycystic 
ovaries.3 
¾ Adrenal causes-tumours, CAH, Cushing’s syndrome 
¾ Drug induced hirsutism is due to the following drugs.  
• Anabolic steroids 
• Metoclopramide 
• Phenothiazines 
• Progestins 
• Reserpine 
• Testosterone 
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Other causes include severe insulin resistance, anorexia nervosa, 
hyperprolactinemia, acromegaly, hypothyroidism and porphyria. Androgen 
secreting tumours of the ovary or adrenal gland usually present with virilization. 
Arrhenoblastoma, sertoli leydig cell tumour, theca cell tumour and some cases of 
granulosa cell tumour cause virilization. 
Signs of virilization are 
• Acne 
• Seborrhea 
• Clitoromegaly 
• Deepening of voice 
• Increased libido 
• Increased muscle mass 
• Infrequent or absent menses 
• Loss of breast tissue or normal female contour 
• Temporal hair recession and balding.  
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PICTURE NO.5 
PICTURE OF A SUBJECT WITH CLITOROMEGALY 
 
 
 
 
 
 
 
 
 
 
 
(This subject presented with amenorrhea and virilization. She underwent TAH 
with BSO. She was diagnosed as having Sertoli Leydig cell tumour). 
             Androgen secreting tumours of the ovary or adrenal are usually heralded 
by virilization, rapid progression of hirsutism and cessation of menses. Androgen 
secreting adrenal tumours are less common10. 
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PICTURE NO.6 
PICTURE OF A SUBJECT WITH FRONTAL HAIR LOSS 
(She was diagnosed as having malignant granulosa cell tumour) 
 
 
 
 
 
 
 Thin skin striae or bruising are signs of hypercortisolism. Although 
hirsutism is the most common complaint associated with hyperandrogenism, 
signs of virilization reflect higher serum androgen levels. 
Although rare, Cushing’s syndrome should be considered in the 
differential diagnosis. It may be due to increased production of 
adrenocorticotropic hormone by the pituitary, adrenal carcinoma/adenoma or 
secretion of adrenocorticotropic hormone. Profound hirsutism is seen most 
commonly in patients with macronodular hyperplasia3.                                     
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REVIEW OF LITERATURE 
 
 
REVIEW OF LITERATURE 
Male-like hair growth, masculinization of women and ambiguity of gender 
has fascinated mankind for millennia, frequently appearing in mythology and the 
arts. The earliest reports of androgen excess, beginning 400 years BC focused on 
the appearance of male like hair growth and features in women often accompanied 
by menstrual cessation. The first of the etiologies identified were adrenal 
disorders, primarily adrenocortical neoplasms and adrenal hyperplasia. 
Kozloviene et al ., at Lithuania studied clinical and hormonal changes in 
women aged 18 – 35 years who complained of hirsutism and concluded that 
significantly higher levels of testosterone and dehydroepiandrosterone sulfate, 
higher levels of free androgen index and lower levels of sex hormone binding 
globulin (p<0.01) were found in females with hirsutism. The females with 
hirsutism complained more frequently of infertility, increased greasiness of skin, 
had higher body mass index, higher systolic and diastolic blood pressure, larger 
waist and hip circumference and higher WHR.11 
 Escobar and San Mill et al., concluded that basal serum 17(OH) 
progesterone measurement has an excellent diagnostic performance for congenital 
adrenal hyperplasia and CAH needs to be excluded in hyperandrogenic women.12 
 Carmina and Rosato et al ., concluded that classic PCOS is the most 
common androgen excess disorder and mild androgen excess disorders like 
ovulatory PCOS and idiopathic hyperandrogenism are also common.13 
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In a study by Azziz et al., on 873 patients, the prevalence of androgen 
secreting neoplasms was 0.2%, 21 hydroxylase deficient classic CAH was 0.6% , 
21 hydroxylase deficient nonclassic CAH was 1.6%, hyperandrogenic insulin 
resistant acanthosis nigricans (HAIRAN) syndrome was 3.1%, idiopathic 
hirsutism was 4.7% and PCOS was 82% . The study showed that hirsutism, 
menstrual dysfunction or acne improved in the majority of patients treated with a 
combination suppressive therapy but alopecia did not improve on treatment.14 
 Pekhlivanov et al., concluded that in women with expressed hirsutism, it is 
more appropriate to apply metformin as a monotherapy or in combination with 
programs for body weight reduction. Hirsutism improved when metformin was 
given.15 
 Carmina et al., concluded that the addition of dexamethasone to 
antiandrogen therapy for hirsutism prolonged the duration of remission.16 
 In a study conducted by Marescalchi et al ., at Institute of Obstetrics & 
Gynaecology, University of Bologna, Italy, it was concluded that despite different 
effects on androgen levels, flutamide, finasteride and EE-CPA constitute very 
satisfactory alternative therapeutic regimens in the treatment of hirsutism.17 
 Seaman and De Vries et al ., concluded that the risk of venous 
thromboembolism associated with EE-CPA does not differ significantly from that 
associated with the use of conventional COCs18. 
 Cochrane data base analysis showed that OCP containing EE-CPA 
resulted in subjective improvement in hirsutism.19 
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 Fleming et al ., compared the efficacy of metformin with OCP containing 
cyproterone acetate in the management of hirsutism20. 
 Falsetti et al ., showed the effect of long term treatment (60 cycles) with 
the EE-CPA Pill and the follow up after 6 months from cessation in PCOS. Mild 
to moderate hirsutism disappeared in 36 – 60 cycles, where as severe hirsutism 
decreased substantially but persisted after 6 months from the end of the therapy. 
Endocrine parameters were identical to the starting ones. Acne and hirsutism 
reappeared whereas ovarian morphology was in between the initial and final 
condition.21 
 Rautio et al., at Finland studied the effects of metformin and EE-CPA on 
lipid levels in obese and nonobese women with PCOS. HDL increased, and serum 
triglyceride levels decreased during metformin therapy. In the OCP group, total 
cholesterol increased, HDL increased, total cholesterol/HDL decreased and TGL 
and LDL remained unchanged. Both systolic and diastolic pressures decreased 
over 6 months of metformin treatment. It had been shown that EE-CPA with 
metformin has been shown to improve the lipid profile and insulin sensitivity in 
nonobese women with PCOS.22 
 Aesha sadaf Hameed et al., made a comparative analysis between ethinyl 
estradiol with CPA with or without metformin in the treatment of PCOS induced 
hirsutism. Metformin when added to OCP containing CPA has a better outcome in 
treating hirsutism, menstrual irregularity and BMI reduction23. 
14 
 
15 
 
 Ancuta Gheorghisan – Geluteanu reported a Sertoli Leydig cell tumour in 
postmenopausal women with hirsutism. There was marked reduction in hirsutism 
after resection of tumour.10 
 V ATAY, C CAM, M MUHCU et al ., 2006 concluded that letrozole is 
associated with better ovulation  induction 16.5% and higher pregnancy rate and 
as a first line treatment for anovulatory patients with PCOS.24 
 In a study conducted by 2 clinics in Berlin and Hamburg in 170 
Oligomenorrheic patients, hyperandrogenemia (increased testosterone and / or 
DHEAS) was seen in 41.8%, hyperprolactinemia in 25.9%, abnormal thyroid 
function (TSH and / or TRH induced TSH) in 21.7% and hypergonadotropic FSH 
levels in 3.5% of all patients25.  
 
  
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
AIM OF THE STUDY 
 There are not many studies that look at the causes of hirsutism, their 
clinical profile and hormonal changes .Therefore, this study was undertaken to 
analyse the clinical profile, biochemical profile, various causes of hirsutism and 
the response to treatment. 
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MATERIALS AND METHODS 
 
 
 
 MATERIALS AND METHODS 
Study design 
 This is a prospective study. 
Period of study 
 The period of study was from August 2010 to September 2011 
Place of study 
Subjects were taken from  Endocrinology clinic and Fertility  Research 
centre, Institute of Obstetrics and  Gynaecology,  Govt Hospital for Women and 
Children, Egmore. 
Inclusion Criteria 
Females with modified Ferriman-Gallwey scoring >8 were included in the 
study. 
After getting an informed consent from the subjects, they were subjected 
to clinical and biochemical evaluation after history taking. 
Exclusion criteria 
Women who were 60 years and above and pregnant women were excluded 
from the study 
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History 
History of presenting complaints were enquired 
Age of onset of hirsutism and duration were asked. This is because severe 
hirsutism can occur in a short duration in androgen secreting tumours. Longer 
duration of hirsutism is present in idiopathic hirsutism. 
 
Menstrual history: Any histories of irregular cycles or amenorrhoea were 
asked for. Menstrual complaints are common in PCOS, hypothyroidism, CAH and 
androgen secreting tumours.  Amenorrhea is more common in CAH and androgen 
secreting tumours. 
 
Duration of infertility: Infertility is common in PCOS.  Elevated 
androgen levels prevent ovulation leading to infertility. 
Recent weight gain: Weight gain occurs in PCOS, hypothyroidism, insulin 
resistance. Peripheral fat favours the conversion of testosterone to 
dihydrotestosterone. Weight loss is seen in malignant tumours. 
 
History of drug intake: 
 Several drugs cause hirsutism. Name of the drug taken and the duration of 
the drug intake were also enlisted. 
 
Clinical examination 
 The patients in the study were subjected to clinical evaluation. 
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Hirsutism scoring was made according to modified Ferriman-Gallwey scoring 
system26. 
Height in cm and weight in kg were measured.  
Blood pressure was recorded in the sitting position in the right arm. 
Body Mass index was calculated by the formula, weight in kg/(height in metre)2  
BMI (kg/m2)    weight status 
<18.5     Under weight 
18.5-24.9    Normal 
25.0-29.9    Overweight 
30.0-39.9    Obese 
40.0 and more    Extreme obesity 
Waist circumference (in cm) and hip circumference (cm) were measured 
for all subjects. Waist was measured at the level of belly button and hip was 
measured at the broadest level of the gluteal region. Waist hip ratio was calculated 
for all subjects. Normal WHR is 0.8. WHR > 0.8 is considered as a marker of 
insulin resistance.                                                                                                                 
The subjects were examined for signs of virilization and 
hyperandrogenism like acne, male pattern balding, increased muscle mass, deep 
voice, clitoromegaly, breast atrophy. Acanthosis nigricans was also looked for in 
each subject.  Features of Cushing’s syndrome like moon facies and buffalo hump 
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were also looked for. Features of hyperprolactinemia like milk secretion were also 
looked for. 
USG Pelvis 
 USG evidence of PCOS: Subjects who had 12 or more follicles in each 
ovary with size 2-9 mm and ovarian volume >10ml in one or both ovaries are 
considered as having polycystic ovaries27. Adnexal masses if any or any uterine 
abnormalities were also looked for. 
 
USG Abdomen 
 USG abdomen was taken in cases suspected of congenital adrenal 
hyperplasia or ovarian mass in addition to USG pelvis. 
 
CT Abdomen 
 CT abdomen was taken in cases of congenital adrenal hyperplasia and 
malignant ovarian tumours. 
 
Biochemical Investigations 
Free testosterone and dehydroepiandrosterone sulphate levels from venous 
blood were measured in all individuals. Free testosterone is a more sensitive 
indicator because it is the unbound hormone which causes hirsutism. Venous 
blood for free testosterone was taken from the subjects in the morning. DHEAS is 
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a direct measure of adrenal androgen activity. Hence it was also measured in all 
subjects. 17 (OH) progesterone level was measured in cases suspected of CAH 
and adrenal tumours32. TSH is also measured in all cases since hypothyroidism 
also causes hirsutism. 24hrs urinary cortisol has to be measured in cases suspected 
of Cushing’s syndrome.  Fasting blood sugar was measured from the venous 
blood for all subjects. Fasting blood sugar up to 125 mg/dl was considered as 
normal value and values between 126-200 mg/dl was considered as impaired 
glucose tolerance34. Values >200 mg/dl are considered as DM because insulin 
resistance can also cause hirsutism .100g OGTT is done in cases with fasting 
blood sugar > 125 mg/dl. PCOS is also associated with insulin resistance. Lipid 
profile was taken in all the subjects after 10 hrs fasting in the morning to rule out 
hyperlipidemia. These investigations were done to identify any co morbid 
illnesses like Diabetes mellitus and hyperlipidemia and to treat them at an early 
stage to prevent long term complications like atherosclerosis, stroke etc.  Also 
PCOS is associated with metabolic syndrome.28 
STANDARD LAB VALUES 
• Free testosterone 0.4 - 2.0 pg/ml 
• DHEAS 0.8-10.5 ng/ml 
• TSH-0.5 to 5.5 mU/ml 
• Lipid  profile 
• Total cholesterol <200 mg/dl 
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TGL < 150 mg/dl 
HDL>55 mg/dl 
LDL<130 mg/dl 
Lipid profile and TSH are measured in the morning in empty 
stomach by enzymatic method. 
Treatment 
  Subjects with idiopathic hirsutism and PCOS were given oral 
contraceptive pills containing cyproterone acetate 2mg with ethinyl estradiol 
35mcg for 6months (6 cycles) and the outcome evaluated. The outcome evaluated 
were reduction in severity of hirsutism, regularization of cycles. In those with 
weight gain, metformin is added in a dosage of 500mg BD daily and looked for 
reduction in weight as well.  Previous studies in women with documented PCOS 
have indicated that weight loss reduces insulin resistance and 
hyperandrogenism.28,29,30 
 In those with infertility, OCP containing cyproterone acetate 2mg and 
35mcg  ethinyl estradiol was given for 3 months along with metformin if BMI > 
25 kg/m2. Then letrozole was given for 3 cycles in a dosage of 2.5 mg OD for 5 
days starting from the second day of the cycles. Metformin was also continued.  
Follicular study is done starting from 9th day of cycles and subjects were advised 
intercourse when the follicle reaches 18-20 mm. Subjects were asked to report to 
the hospital if there was a missed period or onset of menses.  Pregnancy was 
confirmed by urine gravindex test and USG pelvis in the first trimester at 8 weeks.  
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In those with ovarian tumours, definitive surgery was done depending on the stage 
and followed by chemotherapy if needed. For late onset congenital adrenal 
hyperplasia, dexamethasone 0.5 mg OD is given and looked for response to 
treatment. This is given to suppress the excess androgen levels. They also show 
features of virilization. They may need procedures like clitoroplasty also. 
 Local therapies 
                    For patients with mild hirsutism, local measures such as shaving, 
bleaching and depilatories may suffice. Shaving is the easiest and safest method. 
Bleaching products are often ineffective for dark hair growth and skin irritation 
may occur. Electrolysis is one of the most and permanent methods of hair removal 
and may be an adjunct to hormonal treatment3. 
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PHARMACOLOGY OF DRUGS 
Pharmacology of drugs used 
Cyproterone acetate combined with ethinyl estradiol acts as a 
contraceptive agent. It is given for 21 days with a gap of 7 days in a cycle. 
Cyproterone acetate has progestational activity which inhibits LH release 
augmenting the direct antiandrogenic action. It competes with dihydrotestosterone 
for the intra cellular androgen receptor and inhibits its binding. 
In case of PCOD, it increases SHBG which binds the free testosterone 
thereby reducing hair growth, acne & dry skin and regularizes the menstrual cycle. 
Side Effects:   
• Prevent pubertal changes (larger doses) 
• Loss of libido (adults) 
• Gynecomastia (males) 
• Amenorrhea (large doses) 
Uses:   
• Contraception ,Acne 
• Virilization (women) 
• Regularization of cycles 
24 
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Metformin: It is a biguanide. It cause little or no hypoglycemia in non diabetic 
individuals and even in diabetics, hypoglycemia is rare. In addition to its action on 
blood sugar, it improves lipid profile in type 2 diabetes. 
Mechanism of action: 
• Suppresses   hepatic gluconeogenesis and glucose output from liver. 
• Enhance insulin – mediated glucose disposal in muscle & fat through the 
transport of GLUT1 from intraceullular site to plasma membrane. 
• Promote peripheral glucose utilization by enhancing anaerobic glycolysis. 
Pharmacokinetics: Excreted unchanged by kidney. 
Adverse effects:  
• Abdominal pain 
• Anorexia 
• Nausea 
• Metallic taste 
• Mild diarrhoea 
• Tiredness 
Letrozole: 
It is an aromatase inhibitor, a orally active nonsteroidal compound. It 
reversibly inhibits aromatization all over the body, resulting in total oestrogen 
deprivation. It has 100% oral bioavailability. 
Use: Ovulation induction. 
Advantages: Causes unifollicualar development. Has no effect on cervical mucus.
  
 
 
 
 
 
 
 
RESULTS AND ANALYSIS 
 
 
RESULTS AND ANALYSIS 
TEST STATISTICS USED WERE 
• Chi – square test 
• two sample ‘t’ test 
• paired ‘t’ test 
The subjects after clinical, biochemical analysis and ultrasonogram 
examination were grouped into PCOD and non PCOD. The treatment was given 
according to the cause of hirsutism. The outcome evaluated were weight 
reduction, regularity of menstrual cycles and reduction in the scoring of hirsutism. 
After treatment, 5 from the PCOD group and 3 from the non PCOD group 
conceived. There were 6 defaulters in the study. Two postmenopausal subjects 
were   advised LASER treatment. They resorted to shaving the facial hair. One 
subject with malignant sertoli leydig cell tumor had recurrence of the tumour and 
died due to metastasis. A p value<0.05 is significant 
TABLE NO.1 
AGE GROUP – GROUP STATISTICS 
Group  No  Mean  Standard 
deviation  
Standard error 
mean 
PCOD  46  24.11  4.175  0.616 
NON 
PCOD 
27  30.15  9.172  1.765 
  
 The mean age in the PCOD group is 24.11 years and in the non PCOD 
group, it is 30.15 years (p value < 0.05). It is statistically significant. 
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TABLE NO.2 
AGE GROUP – CROSS TABULATION 
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27 
CHI- SQUARE TESTS 
 Value df Asymp. Sig 
(2sided) 
Pearson  
Chi-Square 
9.787a 2 .007 
Likelihood Ratio 9.735 2 .008 
Linear-by-Linear 
Association 
7.471 1 .006 
N of Valid Cases 73   
 
a. 1 cells (16.7%) have expected count less than 5. The minimum expected 
count is 3.70. 
We infer that there exists a statistical significance between PCOD and non 
PCOD group with reference to age distribution 
 
TABLE NO.3 
HISTORY OF SUBJECTS WITH HIRSUTISM 
  PCOD  NON PCOD  Significance 
Marital status 
Married 
unmarried 
 
25(34.2%) 
21(28.8%) 
 
12 (16.4%) 
15(20.5%) 
 
p =0.414 
Family 
history of 
hirsutism 
 
12(16.4%) 
 
6(8.2%) 
 
p= 0.711 
Drug intake  0  2  p=0.0296 
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TABLE NO.4 
FAMILY HISTORY OF SUBJECTS WITH HIRSUTISM 
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TABLE NO.6 
DURATION OF HIRSUTISM OF SUBJECTS IN THE STUDY 
GROUP STATISTICS 
GROUPS Total NO  Mean  Standard Deviation 
Standard 
error mean 
PCOD 
 
46  4.89  3.622  0.534 
NON PCOD  27  5.52  5.767  1.110 
The mean duration of hirsutism in the PCOD group is 4.89 years and in the 
non PCOD, it is 5.52 years. It is statistically insignificant. (p=.569) 
INDEPENDENT SAMPLES TEST 
Duration of hirsutism Levene’s Test for 
Equality of Variances 
t-test for Equality of Means 
F Sig. t df Sig (2-
tailed) 
Equal variances 
assumed 
Equal variances not 
assumed 
5.306 .024 -.571 
-.509 
71 
38.250 
.569 
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TABLE NO.7 
BMI OF SUBJECTS WITH HIRSUTISM IN THIS STUDY 
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 CHI-SQUARE TESTS 
  Value  df  Asym.sig (2-sided) 
Pearson Chi-
Square 
16.197a  2  0.000 
Likelihood Ratio  16.893  2  0.000 
Linear-by-Linear 
Association 
14.034 1 0.000 
N of Valid Cases 73   
 
a. 1 Cells (16.7%) have expected count less than 5. The minimum expected 
count is 3.70 
p=0.000 
There exists a statistical significance in the BMI of subjects between the 
PCOD and the non PCOD group. 
TABLE NO.8 
BMI – GROUP STATISTICS 
  Total No:  Mean  Standard 
Deviation 
Standard 
Error Mean 
PCOD  46  29.36  2.813  0.415 
NON PCOD  27  26.39  4.261  0.820 
 
p=0.001 
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TABLE NO.9 
GROUP STATISTICS 
WAIST HIP RATIO OF SUBJECTS WITH HIRSUTISM 
  Total No:  Mean  Standard 
Deviation 
Standard 
Error Mean 
PCOD  46  0.83  0.20  0.003 
NON PCOD  27  0.82  0.033  0.006 
Here p value is 0.095 
Mean waist hip ratio of subjects with PCOD and hirsutism is 0.83 and in 
the subjects in the non PCOD group, the mean waist hip ratio is 0.82. It is 
statistically insignificant. 
INDEPENDENT SAMPLES TEST 
Waist hip ratio Levene’s Test for 
Equality of 
Variances 
t-test for Equality of 
Means 
F Sig. t df Sig. (2- 
tailed) 
Equal variances assumed 
Equal variances not 
assumed 
10.170 .002 1.694 
1.500 
71 
37.598 
.095 
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TABLE NO.10 
BIOCHEMICAL PARAMETERS OF SUBJECTS WITH HIRSUTISM 
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TABLE NO.12 
LIPID PROFILE OF SUBJECTS WITH HIRSUTISM 
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There exists a statistical significance in the elevated TSH levels and 
elevated DHEAS levels between the PCOD and the non PCOD groups. There is 
no statistical significance between the PCOD and non PCOD groups in elevated 
free testosterone levels and hyperlipidemia. 
 
TABLE NO.13 
GROUP STATISTICS- FASTING BLOOD SUGAR 
  Total No:  Mean  Standard 
Deviation 
Standard 
Error Mean 
PCOD  46  88.98  15.937  2.350 
NON PCOD  27  98.04  26.690  5.136 
Here p value = 0.073 
It is statistically not significant. 
TABLE NO.14 
GROUP STATISTICS – FREE TESTOSTERONE LEVELS 
  Total No:  Mean  Standard 
Deviation 
Standard 
Error Mean 
PCOD  46  1.92  1.164  0.172 
NON PCOD  27  2.18  2.048  0.394 
 
Here p value = 0.494. The mean free testosterone level in the PCOD group 
is 1.92 pg/ml and in the non PCOD group it is 2.18 pg/ml.  
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TABLE NO.15 
GROUP STATISTICS – DHEAS LEVELS 
  Total No:  Mean  Standard 
Deviation 
Standard 
Error Mean 
PCOD  46  8.64  1.941  0.286 
NON PCOD  27  8.76  2.114  0.407 
 
 Here p value = 0.806 
 
TREATMENT OUTCOME OF SUBJECTS WITH HIRSUTISM 
TABLE NO.16  
PRE TREATMENT HIRSUTISM SCORING OF SUBJECTS WITH 
HIRSUTISM 
 
 
Total 
No: 
Mean 
Standard 
Deviation 
Standard 
Error 
Mean 
Significant 
Pre 
treatment 
hirsutism  
PCOD  46  11.61  2.695  0.397 
p=0.798 NON 
PCOD 
27  11.44  2.517  0.484 
 
Mean hirsutism score is 11.61 in the PCOD group and 11.44 in the non 
PCOD group. It is statistically insignificant. 
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TABLE NO.17 
REDUCTION OF HIRSUTISM SCORING AFTER TREATMENT IN THE 
PCOD GROUP 
Paired Samples Statistics 
PCOD Group  Mean  No.  Standard 
deviation 
Standard 
error 
Hirsutism 
score Pre 
treatment 
11.69  42  2.789  .430 
Hirsutism Post 
treatment 
10.69  42  3.272  .505 
 
p=0.000 
There is a statistically significant reduction in hirsutism score after 
treatment in the PCOD group. The mean reduction is 1. 
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TABLE NO.18 
REDUCTION IN HIRSUTISM SCORING AFTER TREATMENT IN THE 
NON PCOD GROUP 
 
Non PCOD 
Group 
Mean  No.  Standard 
deviation 
Standard 
error 
Hirsutism 
score Pre 
treatment 
11.59  22  2.462  0.525 
Hirsutism Post 
treatment 
10.41  22  2.282  0.486 
                                                 
p=0.001 
There exists a statistical significance between the hirsutism scores of the 
pre treatment and post treatment Non PCOD subjects. These is a mean reduction 
in score by 1.18 
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 Chi-Square tests 
 Value  df Asymp. 
Sig. (2-
sided) 
Exact 
Sig. (2-
sided) 
Exact 
Sig. (1-
sided) 
Pearson Chi-square 
Continuity correctionb 
Likelihood Ratio 
Fisher’s Exact Test 
N of  Valid Cases 
15.517a
13.110 
 
15.128 
 
64 
1 
1 
 
1 
.000 
.000 
 
.000 
 
 
 
 
.000 
 
 
 
 
.000 
 
 
a. 1 cells (25.0%) have expected count less than 5. The minimum expected 
count is 4.81. 
b. Computed only for a 2x2 table 
p = 0.000 
There is a statistically significant reduction in weight after treatment in 
hirsutism subjects in this study. 
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TABLE NO.20 
OUTCOME OF THE MENSTRUAL CYCLES IN HIRSUTISM SUBJECTS 
AFTER TREATMENT OF HIRSUTISM 
  PCOD  Non PCOD  Total 
Regular 
% of total 
37 
57.8% 
16 
25% 
53 
82.8% 
Irregular cycles 
% of total 
 
2 
3.1% 
1 
1.6% 
3 
4.7% 
Oligomenorrhea 
or 
Amenorrhea 
% of total 
               
3 
 
4.7% 
 
3 
4.7% 
6 
9.4% 
Premature 
menopause 
or 
Surgical menopause 
% of total 
0 
2 
3.1% 
2 
3.1% 
 
 
CHI-SQUARE TESTS 
 
 Value Df Asymp. Sig.  
(2-sided) 
Pearson Chi-
Square 
3.255a 3 .354
Likelihood Ratio 3.078 3 .380
Linear-by-Linear 
Association 
3.040 1 .081
N of Valid Cases 64   
 
a. 6 cells (75.0%) have expected count less than 5. The minimum expected count 
is 1.03. Here p=.081. It is statistically insignificant. 
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USG pictures of subjects with hirsutism    
•  Polycystic ovaries – 46. 
• Hypoplastic uterus with adrenal hyperplasia-1 
• Adnexal mass – 6. 
• Dermoid cyst – 1 
• Endometriotic cyst-1 
• Ovarian mass-4 
• Normal Study – 21
  
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 DISCUSSION 
 A   study by Aesha Sadaf et al., at Bahawalpur, Pakistan showed the age 
range of hirsutism was from 16 to 38 years. In our study the age range of 
hirsutism was from 15 to 51 years23. In our study 65% of PCOS subjects had onset 
of hirsutism between 10 and 20 years whereas 50% of non PCOS subjects had 
onset of hirsutism from 21 and 30 years.  
 In a study on 122 female residents by Kozloviene at al., at Lithuania aged 
18-35 years in 2002-2003 with complaints of hirsutism, hirsutism was present in 
74 (60.66%) females and in 48 females (39.34%) no hirsutism was noted. The 
females with hirsutism complained more frequently of infertility (P<0.05), 
increased greasiness of skin (p<0.05), higher systolic and diastolic blood pressure, 
larger waist and hip ratio (P<0.001), higher levels of testosterone and 
dehydroepiandrosterone sulphate (P<0.05)11.  In our study, the subjects 
complained of infertility (p=.012), irregular cycles (n=31) % oligomenorrhoea or 
amenorrhea (n=12). Increased waist hip ratio was seen in 14 subjects, increased 
free testosterone in 24 cases and increased DHEAS in 15 subjects(p=.038) in our 
study.  Two subjects with hirsutism had premature ovarian failure .  They had 
increased FSH and LH. They were given hormone replacement therapy. 
 In a study by Carmina et al., at Palermo, Italy between 1980 and 2004, the 
prevalence of androgen excess disorders was PCOS (72.1%), idiopathic 
hyperandrogenism (15.8%), idiopathic hirsutism (7.6%), 21-hydroxylase – 
deficient non classic congenital adrenal hyperplasia (4.3%), androgen secreting 
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tumours (0.2%)13. In our study conducted between August 2010 and September 
2011, the prevalence of PCOS was 63.01%, idiopathic hirsutism 0.44%, 
hypothyroidism 0.08% androgen secreting ovarian tumours 0.05%, premature 
ovarian failure (0.02%), drug induced hirsutism 0.02%, late onset congenital 
adrenal hyperplasia 0.014%12. A 15 years old girl who presented with features  of 
virilization including hirsutism was diagnosed as congenital adrenal hyperplasia- 
late onset type. 
 In the study by Azziz et al., at Alabama between October 1987 and June 
2002 in 873 subjects, the prevalence of androgen secreting neoplasm was 0.2%, 
21-hydroxylase-deficient classic adrenal hyperplasia was 0.6% 21-hydroxylase – 
deficient nonclassic adrenal hyperplasia was 1.6%, hyperandrogenic insulin –
resistant acanthosis nigricans (HAIRAN) syndrome was 3.1%, idiopathic 
hirsutism was 4.7% and PCOS was 82%. Fifty-nine patients (6.75%) had elevated 
androgen levels, hirsutism and normal ovulation. A total of 257 patients were 
included in the assessment of the response to hormone therapy. The mean duration 
of follow up was 33.5 months (range 6-15.5). Hirsutism improved in 86%, 
menstrual dysfunction in 80%, and hair loss in 33% of patients14. 
 In our study, free testosterone levels were elevated in 24 subjects 
(24/73=32.87%). DHEAS in 14/73=19.17%), abnormal lipid profile in 
12/78=16.4%), elevated TSH in 8 subjects (10.95%). The response was assessed 
in 64 subjects after 6 months of treatment. Subjects who were post menopausal 
(n=2) were advised laser treatment. They did not go for laser treatment. They 
opted for shaving the excess hair in the face. They used to shave once in two 
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weeks. 17 subjects in the PCOS group and 13 subjects in the non PCOS group 
showed reduction in the severity of hirsutism. Probably the others needed an 
increase in the dosage of cyproterone acetate or duration of treatment. However 
all of them need to be followed up after 1 year whether there is recurrence or not. 
4 subjects were diagnosed as having diabetes mellitus in our study (1 in the PCOD 
group and 3 in the non PCOD group). 1 subject with PCOD was diagnosed as 
having impaired glucose tolerance.   
 In a study by Carmina et al., androgen levels remained low after 1 year of 
treatment with dexamethasone along with spironolactone16. In our study, we gave 
treatment for 6 months only but did not measure post treatment free testosterone 
levels. There was statistically significant reduction in the severity of hirsutism in 
both PCOS and non PCOS groups. We did not follow up the patient after 1 year in 
our study. In their study, those who were treated with spironolactone only, the 
hirsutism scores returned to baseline scores after 1 year. 
 A study by Marescalchi et al., Italy showed that OCP containing EE-CPA 
was most efficacious in treating hirsutism17. In their regimen the dosage of EE is 
0.01 mg in first week, 0.02 mg EE/Day for second week and 0.01 mg EE/day in 
third week with a gap of 7 days, then 12.5 mg CPA/day during first 10 days of 
every month for 12 months23. In our regimen OCP containing EE-CPA in dosage 
of 35 mcg of ethinyl estradiol and 2 mg of cyproterone acetate for 21 days in a 
month with a gap of 7 days was given for 6 months. Metformin was given 
additionally in a dosage of 500 mg BD if BMI is >25 kg/m2. In their study, the 
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hirsutism scoring was done after 6, 9 and 12 months. The decrease was -60±18%, 
-20±11%, 28±21% after 6,9 and 12 months respectively. 
 In our study the hirsutism scoring was done after 6 months of treatment. 
The cycles became regular in 46.57% PCOS subjects and 19.17% non PCOS 
subjects, remained irregular in 4.8% PCOS cases and 4.5% of non PCOS subjects. 
4.7% PCOS subects were oligomenorrhoeic and 7.8% non PCOS subjects were 
amenorrhoeic in our study. 
 In a study by K Rautio et al., 35 women with PCOS (18 obese and 17 
nonobese) were randomised to 6 months treatment with metformin or EE2-CPA 
OCP28. Metformin treatment had beneficial effects on lipid profile and blood 
pressure and therefore it could be useful in the prevention of cardiovascular 
complications in these women22. In our study, metformin was used for subjects 
with BMI>25 kg/m2, but follow up of the subjects with post treatment lipid profile 
was not done. 11 of the subjects in our study had abnormal lipid profile (ie, 
elevated total cholesterol and elevated low density lipoprotein). 
 There are not many studies in androgen secreting ovarian tumours. In our 
study, there were 4 cases of androgen secreting ovarian tumours. There was one 
malignant granulosa cell tumour, one juvenile granulosa cell tumour, two 
malignant sertoli leydig cell tumours. All the four had features of virilization. Of 
these, 3 showed marked reduction in severity of hirsutism, but the clitoromegaly, 
breast atrophy, hoarseness of voice did not change. One case of malignant sertoli 
leydig cell tumour stage 3 developed recurrence after 6 months and died due to 
lung metastasis. 
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There were 6 subjects with hypothyroidism in the non PCOD group.  
They were given EE-CPA along with thyroxine for six months. 5 subjects showed 
reduction in the severity of hirsutism by 1 to 3 scores. 1 subject showed no 
reduction in the severity of hirsutism. 
One subject with PCOD showed frontal hair loss. She was obese with BMI 
of 30.01kg/m2, had elevated LDL, cholesterol and TGL.  She came with 
complaints of infertility and irregular cycles once in 3 to 6 months. She was given 
metformin along with EE-CPA for 3 months. She had a hirsutism score of 21.  
She showed reduction in weight and she had regular cycles after 3 months.  She 
was started on letrozole from the second day of periods but she failed to conceive. 
She also showed no reduction in the severity of hirsutism. 
Obesity has a negative impact on the efficacy of the treatment of hirsutism. 
Hence appropriate lifestyle advice is necessary for a successful treatment 
programme30. 
  
50 
 
PICTURE NO.7 
PICTURE OF A SUBJECT WITH PCOD WITH FRONTAL HAIR LOSS 
 
PICTURE NO.8 
PICTURE OF A SUBJECT WITH ANDROGEN SECRETING OVARIAN 
TUMOUR WITH FRONTAL BALDNESS 
 
 
         
 
 
 
She underwent TAH with BSO. Histopathology report came as Juvenile 
Granulosa Cell Tumour. 
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    Any disturbance in ovarian androgen metabolism will profoundly affect the 
reproductive state of a woman35.  Significance of elevated serum LH, insulin 
resistance or polycystic appearing ovaries assessed by USG for the diagnosis of 
PCOS remains uncertain. Hyperandrogenism and chronic anovulation are 
mandatory for the diagnosis of PCOS36. Polycystic ovaries are common in normal 
women37. Women who are overweight can expect an improvement in their 
symptoms if they lose weight38,39. Pharmacologic and non pharmacological 
methods are used for hirsutism. Advances in laser hair removal methods and 
topical hair growth retardants offer new options40. 
 Our study has shown that OCP containing EE-CPA along with metformin 
has been effective in reducing body weight and regularization of cycles and mild 
reduction in the severity of hirsutism. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
                                               SUMMARY 
 
 
 
 
                                               SUMMARY 
In this study, 52 had ovarian causes, (46 – PCOS, 4- ovarian tumour, 2- 
premature ovarian failure), one had adrenal cause (late onset CAH), systemic 
cause (hypothyroid -6) for hirsutism. 
• Majority of cases of hirsutism in this study fall in the 21 – 30 years age 
group. 
• In addition to hirsutism, menstrual irregularity is the chief complaint 
• Majority had hirsutism scoring of 9 to 11. Severe hirsutism (Scoring more 
than > 15) was seen in androgen secreting ovarian tumour and PCOS (4 
cases) 
• Virilization features commonly were seen in all the 4 ovarian tumors and 
late onset CAH . Highly elevated free testosterone levels were seen in 
androgen secreting ovarian tumours and late onset congenital adrenal 
hyperplasia. 
• Subjects with hirsutism were either overweight or obese except ovarian 
tumours and CAH.  
• Co morbid conditions like hyperlipidemia, diabetes mellitus, hypertension 
were seen in few PCOS and few non PCOS subjects. 
• Level of the testosterone did not correlate with the severity of hirsutism in 
the PCOS group. 
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CONCLUSION 
 
 
CONCLUSION 
 
This study evaluates the various causes of hirsutism, their clinical and 
biochemical profile and their outcome after treatment. Although PCOS is the most 
common cause for hirsutism, other causes should also be thought of. The 
treatment should be individualised depending upon the cause of hirsutism. We 
should have a high suspicion of virilizing tumours if features of virilization are 
present.   Hirsutism has a response to OCP containing cyproterone acetate but the 
reduction in severity of hirsutism is mild. They might need increase in the 
duration of treatment and dosage of cyproterone acetate. Free testosterone and 
DHEAS may or may not be elevated in PCOS. Majority have normal levels. Free 
testosterone is highly elevated in androgen secreting ovarian tumours. This study 
has highlighted the importance of evaluating the other causes of hirsutism such as 
androgen secreting ovarian tumours and adrenal hyperplasia. Hirsutism causes 
cosmetic problem and psychological upset on a woman. It can also be a 
manifestation of an underlying health problem. Hence it should be properly 
treated so that a favourable outcome can be obtained. 
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CLINICAL & BIOCHEMICAL PROFILE OF WOMEN 
PRESENTING WITH HIRSUTISM AND ITS TREATMENT 
OUTCOME-A PROSPECTIVE STUDY 
PROFORMA 
Name :    Age:    IP/OP No: 
Presenting complaints: 
Hirsutism: Age of onset:  
  Duration: 
Menstrual history: 
    Duration: 
Oligomenorrhoea: 
Amenorrhoea: 
Marital history:  
Duration of infertility: 
Recent weight gain: 
History of drug intake –specify name of the drug and duration of drug intake 
Past history: Previous history of any treatment 
Clinical examination  Ht Cm BMI Kg/m2 BP mm Hg 
Hirsutism scoring  Wt Kg WHR 
MODIFIED FERRIMAN -GALLWEY SCORING SYSTEM 
Each area is given a score of 1 to 4 
1 –mild; 2-moderate; 3- complete light coverage; 4-heavy coverage 
Areas 
• UPPER LIP 
• CHIN  
• UPPER BACK 
 
 
• LOWER BACK 
• UPPER ARMS 
• THIGHS 
• CHEST 
• UPPER ABDOMEN 
• LOWER ABDOMEN 
Score >8 is considered as hirsutism 
Signs of virilization and hyperandrogenism 
Acne 
Hirsutism 
Male pattern balding 
Increased muscle mass 
Deep Voice 
Clitoromegaly 
Breast atrophy 
Acanthosis nigricans 
Features of Cushing’s syndrome like moon facies, buffalo hump are also looked 
for. Features of hyperprolactinemia like milk secretion are also seen in all 
subjects. 
INVESTIGATIONS 
Serum free TESTOSTERONE 
DHEAS 
17(OH) PROGESTERONE in subjects with suspected congenital adrenal 
hyperplasia. 
FASTING BLOOD SUGAR 
LIPID PROFILE 
 
 
24 HOUR FREE URINARY CORTISOL (if CUSHING’S SYNDROME is 
suspected) . 
TSH  
USG pelvis 
USG abdomen if needed 
CT abdomen if needed 
TREATMENT 
• METFORMIN if BMI> 25 kg/m2 
• OCP containing cyproterone acetate 2mg & ethinyl estradiol 35 
microgram. 
• OVULATION INDUCTION with  LETROZOLE 
FOLLOW UP IS DONE AFTER 6 MONTHS 
• REGULARISATION OF CYCLES is enquired into each subject. 
• SEVERITY OF HIRSUTISM is assessed by modified Ferriman- Gallwey 
scoring system after treatment for 6 months. 
• REDUCTION IN WEIGHT is assessed by measuring in Kg & comparing 
the pretreatment weight. 
• CONCEPTION .Pregnancy is confirmed by urine gravindex and 
ultrasonogram pelvis in 1st trimester.  
 
 
 
 
 
 
 
INFORMED CONSENT FORM  
CLINICAL AND BIOCHEMICAL PROFILE OF WOMEN 
PRESENTING WITH HIRSUTISM AND ITS TREATMENT 
OUTCOME-A PROSPECTIVE STUDY 
Study Centre :  Institute of Obstetrics & Gynaecology. 
   Madras Medical College,Chennai-600 008. 
Patient Name : 
Patient Age : 
IP/ OP NO : 
PART – I 
 Hirsutism in the female means an excessive production of hair with a 
tendency to male distribution “Excessive” is defined as beyond social 
acceptability or causing embarrassment to the patient. 
 Causes: Idiopathic, PCOS, Androgen producing tumours, Congenital 
Adrenal Hyperplasia, Drugs (Phenytoin, Diazoxide, Minoxidil, Androgen 
Containing Compounds) 
 The study is being performed to find the various causes of hirsutism by 
appropriate clinical and biochemical methods. 
 I am giving consent for taking blood, urine, ultrasonogram and clinical 
examination. 
 I have been informed that I will be given treatment according to the cause 
as per the hospital guidelines. 
 After the treatment there will be reduction in the severity of hirsutism, 
regularization of cycles, conception and/or reduction in weight. 
 
 
 
 
PART – II 
Patient may check () these boxes 
 I confirm that I have read and understood the Information Sheet for the 
above study. I have the opportunity to ask questions and all my questions and 
doubts have been answered to my complete satisfaction. I have been informed 
about the reason for investigating the cause of my hirsutism 
 I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my legal rights 
being affected. 
 I understand that the Clinical study personnel, the Ethics Committee and 
the Regulatory Authorities will not need my permission to look at my health 
records both in respect to the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study. I agree to this 
access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the 
law. I agree not to restrict the use of any data or results that arise from the study. 
 I agree to take part in the above study and to comply with the instructions 
given during the study and to faithfully co-operate with the study team, and to 
immediately inform the study staff if I suffer from any deterioration in my health 
or well being or any unexpected or unusual symptoms. 
 I hereby consent to participate in this study on Clinical and Biochemical 
profile of Hirsutism. 
 I hereby give permission to undergo complete clinical examination 
diagnostic tests including hematological, biochemical, radiological tests. 
Signature/ Thumb Impression:  Place   Date 
Patient’s Name, Address & Ph No: 
Name of the witness    Witness signature Date 
Signature of the investigator:   Place   Date 
Study investigator’s Name: 
 
 
  
 
 
  
 
 
 
 
ABBREVIATIONS 
SHBG    -  Sex hormone binding globulin 
PCOS    - Polycystic Ovarian Syndrome 
DHEA   - Dehydroepiandrosterone 
17(OH) Progesterone - 17 hydroxy  Progesterone 
DHEAS  - Dehydroepiandrosterone Sulphate 
CAH   - Congenital Adrenal Hyperplasia 
BMI    - Body Mass Index 
CT   - Computed tomography 
USG   - Ultrasonogram 
TSH   - Thyroid stimulating hormone 
CHO   - Cholesterol 
TC   -  Total cholesterol 
HDL   - High density lipoprotein 
LDL   - Low density lipoprotein 
VLDL   - Very low density lipoprotein 
EE-CPA   - Oral contraceptive pill containing  
   cyproterone  acetate 2mg and Ethinyl  
   estradiol 35 microogram 
COCs   - Combined oral contraceptive pills 
OCP   - Oral Contraceptive Pill 
TRH   - Thyrotropin releasing hormone 
FSH   - Follicle stimulating hormone 
LH                               -           Leutinizing hormone
SL.
NO NAME AGE M/s 
PRIMARY PRESRENTING COMPLAINTS 
DUR . 
HIRS HIRS.SCORE 
BMI(kg/
m2) WHR 
OTHE
RS 
FAMILY 
DRUG 
INTAKE USG 
INFERTILI
TY  MENSTRUAL 
WEIGHT 
GAIN HISTORY 
1 SHEELA 20 1 1 2 1 3 11 32.04 0.84 0 NO - PCOD 
2 ANANDHI 27 1 1 2 2 10 12 24.4 0.82 0 NO - PCOD 
3 SREEMATHY 22 1 1 1 1 11 13 27.38 0.83 0 NO - PCOD 
4 
MARAGATH
M 26 1 1 1 1 7 10 31 0.84 0 NO - PCOD 
5 PRIYA 24 1 1 1 1 2 14 28.32 0.84 1 NO - PCOD 
6 MAHA 25 1 1 2 1 7 11 32 0.85 0 YES - PCOD 
7 SHAFEEN 23 1 1 1 1 10 12 28.88 0.83 1,2,7,9 NO - PCOD 
8 AISHA 21 1 1 1 1 5 9 30 0.84 1 YES - PCOD 
9 MALATHY 25 1 1 2 1 11 9 30 0.83 1 YES - PCOD 
10 NAGAKANI 25 1 1 2 1 5 11 30 0.84 0 NO - PCOD 
11 ANANDHI 20 1 1 2 1 3 10 28 0.83 0 NO - PCOD 
12 SUGUNA 30 1 1 1 1 14 11 31 0.84 1 NO - PCOD 
13 SUMATHY 30 1 1 1 1 3 10 28.8 0.84 2,7 NO - PCOD 
14 MUNIAMA 30 1 1 1 1 5 14 31 0.85 2 YES - PCOD 
15 UMA 23 1 1 1 1 4 11 28 0.84 0 NO - PCOD 
16 JAYANTHY 26 1 1 1 1 2 14 35 0.85 2 YES - PCOD 
17 HEMAVATHY 26 1 1 2 1 11 13 28 0.81 0 NO - PCOD 
18 MARYDIANA 29 1 1 1 1 12 12 31 0.82 1 YES - PCOD 
19 PRAMILA 29 1 1 1 1 5 9 30.66 0.84 1 YES - PCOD 
20 MEENA 30 1 1 1 1 1 12 36.21 0.9 2,7 YES _ PCOD 
21 MAMATA 21 1 1 1 1 3 13 30 0.8 1 NO _ PCOD 
22 SUMATHY 28 1 1 1 1 8 21 30.01 0.88 2,3 NO _ PCOD 
MASTER CHART 
 
 
SL.NO NAME 
FBS 
mg/dl 
LIPID 
PROFILE 
FREE 
TESTOSTERO
NE (pg/ml) 
DHEAS(ng
/ml) 
17(OH
)P 
ng/ml TSH(mU/ml) TREATMENT 
OUTCOME 
WT 
REDUCT
ION 
MEN
STRU
L 
CYCL
ES 
HIRS 
SCOR
E 
CONCEPTI
ON 
1 SHEELA 62 NORMAL 2 pg/ml 4.5 _ NORMAL K,M×3&L,M×3 YES 1 8  - 
2 ANANDHI 68 NORMAL 1 8 _ NORMAL K,M×3&L,M×3 NO 1 11 
CONCEIVE
D 
3 SREEMATHY 88 NORMAL 2.52 8.5 _ NORMAL K,M×3&L,M×3 YES 1 13  - 
4 MARAGATHM 75 NORMAL 3.09 11 _ NORMAL K,M×3&L,M×3 YES 1 10  - 
5 PRIYA 84 NORMAL 1.91 8 _ NORMAL K,M×3&L,M×3 YES 1 10 
CONCEIVE
D 
6 MAHA 89 NORMAL 2 8 _ NORMAL K,M×3&L,M×3 YES 1 11  - 
7 SHAFEEN 168 ABNORMAL 4.2 11 _ NORMAL DEFAULTED 
8 AISHA 108 NORMAL 4.25 12 _ NORMAL DEFAULTED 
9 MALATHY 94 NORMAL 1 5 _ NORMAL 
K,M×3&L,M×
3 YES 1 8 
CONCEIVE
D 
10 NAGAKANI 84 NORMAL 2.61 8 _ NORMAL 
K,M×3&L,M×
3 YES 1 10 
CONCEIVE
D 
11 ANANDHI 86 NORMAL 1 7 _ NORMAL 
K,M×3&L,M×
3 YES 1 8 
CONCEIVE
D 
12 SUGUNA 84 NORMAL 2 8 _ NORMAL 
K,M×3&L,M×
3 YES 2 11  - 
13 SUMATHY 72 NORMAL 4 11 _ NORMAL 
K,M×3&L,M×
3 YES 1 10  - 
14 MUNIAMA 89 NORMAL 1.4 7 _ NORMAL 
K,M×3&L,M×
3 YES 1 14  - 
15 UMA 88 NORMAL 2 10.4 _ NORMAL 
K,M×3&L,M×
3 YES 1 9  - 
16 JAYANTHY 90 ABNORMAL 1.2 10.4 _ NORMAL 
K,M×3&L,M×
3 YES 1 14  - 
17 HEMAVATHY 92 NORMAL 0.7 8.2 _ NORMAL 
K,M×3&L,M×
3 YES 1 8 
CONCEIVE
D 
18 MARYDIANA 94 NORMAL 1 10.5 _ NORMAL 
K,M×3&L,M×
3 YES 1 12  - 
19 PRAMILA 91 NORMAL 5.8 6.8 _ NORMAL 
K,M×3&L,M×
3 YES 1 9  - 
20 MEENA 130 ABNORMAL 1.2 10.4 _ NORMAL 
K,M×3&L,M×
3 YES 1 12  - 
21 MAMATA 82 NORMAL 0.9 8 _ NORMAL 
K,M×3&L,M×
3 YES 1 13   
22 SUMATHY 88 ABNORMAL 2 8 _ NORMAL 
K,M×3&L,M×
3 YES 1 21   
 
 
SL.NO NAME 
AG
E M/s 
PRIMARY PRESRENTING COMPLAINTS 
DUR . 
HIRS HIRS.SCORE 
BMI(Kg/ 
m2) 
W
HR 
OTHE
RS 
FAMILY 
DRUG 
INTA
KE USG INFERTILITY  
MENSTRUA
L WEIGHT GAIN HISTORY 
23 REKHA 19 2 2 1 1 7 9 30 .84 1 YES - PCOD 
24 SUVAHANI 21 2 2 1 1 11 9 29.06 0.84 0 NO _ PCOD 
25 SUMATHY 19 2 2 1 1 7 11 32 0.84 0 YES _ PCOD 
26 NIRMALA 21 2 2 1 1 4 11 25 0.8 1 NO _ PCOD 
27 DURGA 23 2 2 1 1 5 11 34.2 0.86 1 NO _ PCOD 
28 THARA 25 1 2 1 1 6 12 30 0.84 1 YES _ PCOD 
29 SARADHA 30 2 2 1 1 6 16 28 0.82 1 NO _ PCOD 
30 STELLAMARY 30 1 2 2 1 3 13 33.71 0.87 2 NO _ PCOD 
31 GEETHA 32 1 2 1 1 6 11 29 0.83 0 NO _ PCOD 
32 HEMAMALINI 20 2 2 1 1 3 9 28 0.8 0 NO _ PCOD 
33 PRABAVATHY 22 2 2 1 1 7 17 32 0.84 1,2 YES _ PCOD 
34 SINDHUJA 22 2 2 1 2 2 13 20.54 0.8 1 NO _ PCOD 
35 PRIYA 20 2 2 1 1 1 20 25.39 0.8 1 NO _ PCOD 
36 SONIA 25 2 2 1 1 1 9 30 0.82 0 NO _ PCOD 
37 JENITA 23 2 2 1 1 1 9 26 0.8 0 NO _ PCOD 
38 PRIYA 32 2 2 2 1 1 9 30 0.84 0 NO _ PCOD 
39 SAHANA 16 2 2 1 1 1 11 29 0.83 1 NO _ PCOD 
40 PRIYA 19 2 2 1 1 1 12 26 0.82 1 NO _ PCOD 
41 JENIFER 18 2 2 1 1 2 10 26 0.83 8 NO _ PCOD 
42 KAVITHA 23 2 2 1 1 1 9 30 0.84 1 NO _ PCOD 
43 VIJI 20 2 2 1 1 2 11 28 0.82 0 NO -_ PCOD 
 
 
 
 SL.NO NAME 
FBS 
mg/dl 
LIPID 
PROFILE 
FREE 
TESTOSTERONE 
(pg/ml) DHEAS(ng/ml) 
17(OH)P 
ng/ml 
TSH(mU/ml
) TREATMENT 
OUTCOME 
WT 
REDUCTIO
N 
MENSTRUL 
CYCLES 
HIRS 
SCORE CONCEPTION 
23 REKHA 82 NORMAL 1.2 7.5 - NORMAL K+Mx6 YES 1 7 - 
24 SUVAHANI 92 NORMAL 1.5 7 _ NORMAL K+M×6 YES 1 9  - 
25 SUMATHY 94 NORMAL 0.8 9.6 _ NORMAL K+M×6 YES 1 8  - 
26 NIRMALA 88 NORMAL 1 10.5 _ NORMAL K×6 NO 1 11  - 
27 DURGA 86 NORMAL 2 7.5 _ NORMAL K+M×6 YES 3 11  - 
28 THARA 86 NORMAL 1.2 8 _ NORMAL K+M×6 YES 1 8  - 
29 SARADHA 88 NORMAL 1.9 8 _ NORMAL K+M×6 YES 3 16  - 
30 STELLAMARY 92 NORMAL 4.6 14.3 _ NORMAL K+M×6 YES 1 11  - 
31 GEETHA 84 NORMAL 0.9 8 _ NORMAL K+M×6 NO 2 11  - 
32 HEMAMALINI 86 NORMAL 0.9 7 _ NORMAL K+M×6 YES 1 9  - 
33 PRABAVATHY 110 ABNORMAL 2 10.5 _ NORMAL K+M×6 YES 2 17  - 
34 SINDHUJA 90 NORMAL 0.9 4.6 _ NORMAL K×6 YES 1 11  - 
35 PRIYA 92 NORMAL 0.8 10 _ NORMAL K+M×6 YES 1 20  - 
36 SONIA 86 NORMAL 1 7 _ NORMAL K+M×6 YES 1 7  -- 
37 JENITA 74 NORMAL 1 6.8 _ NORMAL K+M×6 YES 1 7  - 
38 PRIYA 82 NORMAL 1.5 7.5 _ NORMAL K+M×6 YES 1 9  - 
39 SAHANA 90 NORMAL 1 8.5 _ NORMAL K+M×6 YES 1 12  - 
40 PRIYA 75 NORMAL 1.2 8 _ NORMAL K+M×6 YES 1 12  - 
41 JENIFER 82 NORMAL 1.5 8 _ 
ELEVATE
D K+M+T×6 YES 1 10  - 
42 KAVITHA 94 NORMAL 1.8 9 _ NORMAL K+M×6 YES 3 9  -- 
43 VIJI 84 NORMAL 1.8 9 _ NORMAL DEFAULTED           
 
 
SL.N
O NAME 
AG
E M/s 
PRIMARY PRESRENTING COMPLAINTS 
DUR 
. 
HIR
S 
HIRS.SCOR
E 
BMI(kg/ 
/m2) 
WH
R 
OTHER
S 
FAMILY 
HISTORY DRUG INTAKE USG 
INFERTILIT
Y  
MENSTRUA
L 
WEIGHT 
GAIN 
44 MINI 28 2 2 2 1 1 11 30 0.84 0 NO _ PCOD 
45 
KEERTIK
A 21 2 2 2 1 1 9 29 0.83 0 NO _ PCOD 
46 
MURUGA
M 20 2 2 1 1 3 10 28 0.82 1 NO _ PCOD 
47 MALLIGA 31 1 2 2 2 10 9 21.48 0.8 0 YES _ NORMAL 
48 ARUL 26 1 1 1 1 6 13 32 0.88 2 NO _ NORMAL 
49 NITHYA 30 1 1 2 2 3 11 19.3 0.79 0 YES _ NORMAL 
50 SUMATHY 30 1 1 2 1 10 12 30 0.84 0 NO _ NORMAL 
51 PONNI 24 2 2 2 1 2 11 22 0.8 0 NO _ NORMAL 
52 VENI 28 2 2 2 2 11 12 24 0.8 0 YES _ NORMAL 
53 RANI 27 2 2 2 1 11 12 24.88 0.8 0 NO _ NORMAL 
54 SUJATHA 28 2 2 1 1 10 11 28 0.82 0 YES _ NORMAL 
55 UMARANI 39 2 2 1 2 12 15 20 0.79 9 NO ART for 4 years NORMAL 
56 CHITRA 40 2 2 2 2 15 10 30 0.85 7 YES _ NORMAL 
57 MALLIGA 40 1 2 1 2 4 12 28 0.8 3,5 NO _ 
ADNEXAL 
MASS 
58 ELIZABET 28 1 2 1 1 1 9 25 0.8 0 NO _ NORMAL 
59 GEETHA 40 1 1 1 1 1 9 28 0.84 1 NO DANAZOLx2 years 
ENDOMETRIO
SIS 
60 SARITHA 26 1 2 1 2 2 9 29 0.85 3,5 NO 
CHLORPROMAZINEx5 
years 
ADNEXAL 
MASS 
61 KALA 43 1 2 1 1 2 10 25.39 0.86 7,9 NO _ 
ADNEXAL 
MASS 
62 SHEELA 30 1 2 2 1 5 12 36.21 0.9 0 NO _ NORMAL 
63 
GOVINDA
M 51 1 2 2 1 25 9 30 0.85 7,9 YES _ NORMAL 
64 NAGAMA 50 1 2 1 2 1 20 20 0.76 3,4,5 NO _ 
ADNEXAL 
MASS 
   
 
 
SL.NO NAME 
FBS 
mg/dl 
LIPID 
PROFILE 
FREE 
TESTOSTERONE 
(pg/ml) DHEAS(ng/ML 
17(OH)P 
ng/ml TSH(mU/ml) TREATMENT 
OUTCOME 
WT 
REDUCTION 
MENSTRUL 
CYCLES 
HIRS 
SCORE CONCEPTION 
44 MINI 80 NORMAL 1.8 8 _ NORMAL DEFAULTED           
45 KEERTIKA 86 NORMAL 2 10.5 _ ELEVATED K+M+Tx6 YES 1 9   
46 MURUGAM 84 NORMAL 1.9 9 _ NORMAL K+MX6 YES 1 7   
47 MALLIGA 82 NORMAL 1 8 _ NORMAL Kx3+Lx3 NO 1 9 CONCEPTION 
48 ARUL 120 ABNORMAL 1.8 10 _ NORMAL K+M×3+L+M×3 YES 1 13   
49 NITHYA 102 NORMAL 1 8 _ NORMAL Kx3+Lx3 NO 1 11 CONCEPTION 
50 SUMATHY 100 NORMAL 1 7.5 _ NORMAL K+M×3+L+M×3 YES 1 12   
51 PONNI 94 NORMAL 1.9 10.5 _ NORMAL KX6 NO 1 11   
52 VENI 88 NORMAL 1.4 3.8 _ NORMAL KX6 NO 1 12   
53 RANI 86 NORMAL 1.2 7 _ NORMAL KX6 NO 1 12   
54 SUJATHA 84 NORMAL 1 9 _ NORMAL POF→HRT NO 4 10   
55 UMARANI 160 ABNORMAL 4.2 11 _ NORMAL POF→HRT NO 4 12   
56 CHITRA 158 ABNORMAL 4.6 8 _ NORMAL DEFAULTED 
57 MALLIGA 94 NORMAL 3.9 10.4 _ NORMAL TAH WITH BSO NO 3 10   
58 ELIZABET 88 ABNORMAL 4 7.5 _ ELEVATED K+T×6 NO 1 9   
59 GEETHA 86 NORMAL 0.8 9.6 _ NORMAL PATIENT WENT FOR IVF           
60 SARITHA 78 NORMAL 1.2 7.5 _ NORMAL TAH WITH BSO NO 3 7   
61 KALA 148 ABNORMAL 0.8 8.5 _ NORMAL TAH WITH BSO TOPICAL TREATMENT 
62 SHEELA 98 ABNORMAL 1.2 10.4 _ NORMAL K+M×6 YES 1 10   
63 GOVINDAM 160 ABNORMAL 0.8 7.5 _ NORMAL TOPICAL TREATMENT 
64 NAGAMA 92 NORMAL 5.8 8 _ NORMAL TAH WITH BSO YES 3 15   
 
 
 
 
 
SL.
NO NAME 
A
G
E M/s 
PRIMARY PRESRENTING COMPLAINTS 
DU
R . 
HIR
S 
HIRS.SCO
RE 
BMI(kg/ 
m2) 
WH
R 
OTHER
S 
FAMIL
Y 
DRUG 
INTAK
E USG 
INFERTILI
TY  
MENSTRU
AL 
WEIGHT 
GAIN 
HISTOR
Y 
65 GOMATHY 30 2 2 2 2 2 10 28 .83 0 NO - NORMAL 
66 ANITHA 22 2 2 2 1 3 11 29 0.84 0 NO _ NORMAL 
67 SREEMATHY 25 2 2 1 1 2 10 28 0.82 1 NO _ NORMAL 
68 SELVI 22 2 2 1 1 1 10 30 0.85 1 NO _ NORMAL 
69 DAISY 18 2 2 1 1 1 9 29 0.84 1 NO _ NORMAL 
70 KALIAMA 22 2 2 1 1 1 11 26 0.83 0 NO _ NORMAL 
71 GURUVAMA 30 2 2 1 1 2 12 28 0.82 0 NO _ NORMAL 
72 PRIYA 15 2 2 1 2 5 14 22 0.79 5,6 NO _ 
ADRENAL HYPERPLASIA with HYPOPLASTIC 
UTERUS 
73 RAMAJEYAM 19 2 2 1 2 1 16 19.3 0.76 4,5,6 NO _- ADNEXAL MASS 
 
SL.NO NAME 
FBS 
mg/dl 
LIPID 
PROFILE 
FREE 
TESTOSTERONE 
(pg/ml) DHEAS(ng/ml) 
17(OH)P 
ng/ml TSH(mU/ml) TREATMENT 
OUTCOME 
WT 
REDUCTION 
MENSTRUL 
CYCLES 
HIRS 
SCORE CONCEPTION 
65 GOMATHY 88 NORMAL 1 8 - NORMAL Kx6 YES 1 10 
66 ANITHA 86 NORMAL 1.5 8.2 _ ELEVATED K+M+T×6 YES 1 9   
67 SREEMATHY 84 NORMAL 1 8.5 _ ELEVATED K+M+T×6 YES 1 8   
68 SELVI 82 NORMAL 1 7 _ ELEVATED K+M+T×6 YES 1 7   
69 DAISY 80 NORMAL 0.8 7.5 _ ELEVATED K+M+T×6 YES 1 7   
70 KALIAMA 84 NORMAL 0.9 8.5 _ ELEVATED K+M+T×6 YES 1 9   
71 GURUVAMA 78 NORMAL 1.9 8.5 − NORMAL K+M×6 YES 1 12   
72 PRIYA 75 NORMAL 9.58 13.15 14.5 NORMAL DEXA .5mg OD×6 NO 2 10   
73 RAMAJEYAM 72 NORMAL 3.5 15 − NORMAL TAH WITH BSO RECURRENCE&PATIENT DIED 
KEY TO MASTER CHART 
Sl.No   - Serial number 
M/s   - Marital status 
1   - Married 
2   - Unmarried 
Infertility 
1   - Infertility is present 
2   - No infertility 
Menstrual  - Menstrual complaints 
1   - Regular cycles 
2- Irregular cycles or oligomenorrhoea or 
 
amenorrhoea 
Weight gain 
1 - Weight gain 
2 - No weight gain or loss 
DUR.HIRS - Duration of hirsutism 
HIRS.SCORE - Hirsutism score 
BMI - Body Mass Index 
 WHR - Waist hip ratio 
OTHERS - Include masculinizing features , 
hypertension and diabetes mellitus 
1 - Acne 
2 - Acanthosis Nigricans 
3 - Frontal hair loss 
4 - Breast Atrophy 
5 - Clitoromegaly 
 
 
 
 
6 - Hoarseness of voice 
7 - Hypertension 
8 - Generalised hair loss 
9 - Diabetes Mellitus 
USG - Ultrasonogram 
PCOD - Polycystic Ovarian disease 
FBS - Fasting blood sugar 
TS - Thyroid stimulating homone 
K  ‐  OCP containing cyproterone acetate 
hinyl estradiol 35 mcg 
H 
2mg and  Et
   M ‐  Metformin
L  ‐  Letrozole 
T  ‐  Thyroxine 
P  17 ሺOHሻ ‐  17 hydroxy progesterone 
AS  hate DHE ‐  Dehydroepiandrsterone sulp
POF  ‐                 Premature ovarian failure  
RT  ‐                  Hormone replacement therapy H
 
  TAH WITH BSO  ‐  Total abdominal hysterectomy with 
phorectomy bilateral salpingo oo
IVF    ‐  In vitro fertilization 
erapy ART    ‐  Antiretroviral th
     
 
 
